Evaluation of Dihydrofolate Reductase (Dhfr) Gene, Related to Plasmodium Falciparum Pyrimethamine Resistance in Imported Malaria Cases in Iran

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 89

This Paper With 10 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_REMJ-9-4_007

تاریخ نمایه سازی: 20 دی 1402

Abstract:

Background: Antimalarial drug resistance is one of the important challenges for governments in the fight against malaria. Molecular surveillance of antimalarial drug resistance supports early detection of how the recommended treatments work. This allows immediate action to reduce any threat and prevent it from spreading. Therefore, the aim of this study was to evaluate the frequency of dihydrofolate reductase (dhfr) mutants in Plasmodium falciparum resistance to pyrimethamine in Iranian malaria patients. Materials and Methods: In ۲۰۲۰, ۲۷ patients (۲۱ males and ۵ females) with imported P. falciparum cases were studied. The nested-PCR technique first confirmed the species in all samples and then amplification was done by the semi-nested-PCR method in order to detect single nucleotide polymorphisms (SNPs) in dhfr gene related to pyrimethamine resistance. Results: All samples in the ۱۸S rRNA gene had species-specific bands for P. falciparum strains. In the sequence analysis of pfdhfr gene amplification after comparison with the standard strain (wild type), ۲۱ patients had a double mutation (C۵۹R+S۱۰۸N) and six patients had a triple mutation (N۵۱I+C۵۹R+S۱۰۸N) of pyrimethamine resistance. Conclusion: The results of this study showed that the susceptibility of P. falciparum to pyrimethamine in the treatment of malaria is significantly reducing. These findings can raise concerns about pyrimethamine resistance in P. falciparum. Due to the high emergence of double and triple mutants related to pyrimethamine resistance, the malaria surveillance and treatment systems in Iran, the use of pyrimethamine should be considered.

Authors

Seyyed Ali Shariatzadeh

۱Student Research Committee, Mazandaran University of Medical Science, Sari, Iran

Reza Valadan

Molecular and Cell Biology Research Center (MCBRC), Mazandaran University of Medical Sciences, Sari, Iran

Seyed Abdollah Hosseini

Department of Parasitology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Adel Spotin

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Abbas Shahbazi

Department of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Davood Anvari

School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran

Fattaneh Montazeri

Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran

Javad Javidnia

Student Research Committee, Mazandaran University of Medical Science, Sari, Iran

Shirzad Gholami

Toxoplasmosis Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Fornace KM, Diaz AV, Lines J, Drakeley CJ. Achieving global ...
  • WHO. World malaria report ۲۰۲۱. ۲۰۲۱ ...
  • Vatandoost H, Raeisi A, Saghafipour A, Nikpour F, Nejati J. ...
  • Organization WH. Methods for surveillance of antimalarial drug efficacy. ۲۰۰۹ ...
  • Gholizadeh S, Naseri Karimi N, Zakeri S, Dinparast Djadid N. ...
  • Menard D, Dondorp A. Antimalarial Drug Resistance: A Threat to ...
  • Zhao L, Pi L, Qin Y, Lu Y, Zeng W, ...
  • Aboshanab MAA, New MAAM, New MEMA, New MAA, New NAMA. ...
  • Chaturvedi R, Chhibber-Goel J, Verma I, Gopinathan S, Parvez S, ...
  • Apinjoh TO, Ouattara A, Titanji VP, Djimde A, Amambua-Ngwa A. ...
  • Zhao Y, Liu Z, Soe MT, Wang L, Soe TN, ...
  • Soofi K, Khanjani N, Kamiabi F. The Challenges of the ...
  • Nadim A, Kondrashin A, Goya M, Raeisi A. Malaria Elimination ...
  • Eskandarian A-A, Keshavarz H, Basco LK, Mahboudi F. Do mutations ...
  • Jafari S, Le Bras J, Asmar M, Durand R. Molecular ...
  • Zakeri S, Afsharpad M, Raeisi A, Djadid ND. Prevalence of ...
  • Zakeri S, Farahani MS, Afsharpad M, Salehi M, Raeisi A, ...
  • Rouhani M, Zakeri S, Pirahmadi S, Raeisi A, Djadid ND. ...
  • Sharifi-Sarasiabi K, Haghighi A, Kazemi B, Taghipour N, Mojarad EN, ...
  • Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NP, ...
  • Yaqoob A, Khattak AA, Nadeem MF, Fatima H, Mbambo G, ...
  • Taghdiri A, Nejad Almani PG, Sharifi I, Mohammadi MA, Salari ...
  • Jamshidi E, Eftekhar Ardebili H, Yousefi-Nooraie R, Raeisi A, Malekafzali ...
  • Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, ...
  • Mockenhaupt FP, Teun Bousema J, Eggelte TA, Schreiber J, Ehrhardt ...
  • McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA. ...
  • Mita T. Origins and spread of pfdhfr mutant alleles in ...
  • Ghanchi NK, Ursing J, Beg MA, Veiga MI, Jafri S, ...
  • Khattak AA, Venkatesan M, Khatoon L, Ouattara A, Kenefic LJ, ...
  • Nzila-Mounda A, Mberu E, Sibley C, Plowe C, Winstanley P, ...
  • Mendis K. Mass drug administration should be implemented as a ...
  • Xu C, Wong YK, Liao FL, Jiang T, Wang J, ...
  • Agyeman YN, Newton S, Annor RB, Owusu-Dabo E. Intermittent preventive ...
  • Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-treated ...
  • نمایش کامل مراجع